Trial Profile
A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Etoposide; Irinotecan
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors AB Science
- 29 Jan 2020 This trial has been completed in Greece as per European Clinical Trials Database
- 01 Nov 2019 This trial has been withdrawn prior to enrolment in Slovakia as per European Clinical Trials Database
- 17 Jun 2019 This trial has been completed in France as per European Clinical Trials Database